Since IL-17A has not been directly administered in biologically relevant concentrations in GI tumors, we performed this experiment and found it was effective in reducing tumor growth, concurrent with supporting a cytotoxic immune response. The gene discussed is IL17A; the disease is digestive system neoplasm.